• Humans
• Ethiopia/epidemiology
• Male
• Female
• Helicobacter Infections/blood
• Helicobacter Infections/complications
• Adult
• Middle Aged
• Cross-Sectional Studies
• Electrolytes/blood
• Helicobacter pylori
• Lipids/blood
• Dyspepsia/blood
• Dyspepsia/microbiology
• Risk Factors
• Hemoglobins/analysis
• Hemoglobins/metabolism
• Young Adult
• Anemia/blood
• Anemia/diagnosis

• Ethiopia
• Helicobacter pylori
• Metabolic parameters
• Metabolic syndrome

• Humans
• Metabolic Syndrome/epidemiology
• Cross-Sectional Studies
• Ethiopia/epidemiology
• Male
• Female
• Helicobacter Infections/epidemiology
• Helicobacter Infections/complications
• Middle Aged
• Helicobacter pylori
• Adult
• Aged
• Diabetes Mellitus/epidemiology

• H. pylori infection
• associated factors
• controls
• cross-sectional study
• metabolic syndrome

• Humans
• Helicobacter Infections/epidemiology
• Helicobacter Infections/blood
• Helicobacter Infections/complications
• Female
• Cross-Sectional Studies
• Male
• Ethiopia/epidemiology
• Metabolic Syndrome/epidemiology
• Metabolic Syndrome/blood
• Adult
• Middle Aged
• Helicobacter pylori/isolation & purification
• Young Adult
• Prevalence
• Adolescent
• Risk Factors
• Blood Glucose/analysis

• Eradication
• Helicobacter pylori
• Metabolic profile

It is reported that Helicobacter pylori (H. pylori) infection may be linked to non-digestive tract diseases, such as arteriosclerosis including dyslipidemia, diabetes, obesity, hypertension, and cardiovascular disease. Therefore, we reviewed recent studies available in PubMed dealing with the mechanisms of arteriosclerosis due to H. pylori infection and the effects of H. pylori eradication. Conventional studies suggested that H. pylori infection may increase the risk of arteriosclerosis. A large interventional study is required to clarify the causal relationships and the effects of bacterial eradication.

• Helicobacter pylori infection
• arteriosclerosis
• hypertension

The association between Helicobacter pylori (H. pylori) infection and metabolic syndrome (MetS) determined in different cohorts from different countries is currently inconclusive. In the majority of previous studies, H. pylori infection was diagnosed based on the presence of H. pylori IgG antibody in the serum. However, to the best of our knowledge, only few studies have investigated the association between H. pylori infection and MetS using the urea breath test (UBT) as a diagnostic tool. The present study was performed with the aim of providing a detailed analysis of the association between H. pylori infection, as diagnosed by the UBT method, and MetS in a large community from Zhejiang province in eastern China. The results indicated that H. pylori infection increases the risk of MetS in the aged female population.

• 13C-urea breath test
• Chinese aged women
• Helicobacter pylori
• insulin resistance
• metabolic syndrome

• Ankle brachial index
• Carotid intima media thickness
• Gastrin
• Helicobacter pylori antibody
• Pepsinogen
• Pulse wave velocity

• Helicobacter pylori infection
• dyslipidemia
• glycated hemoglobin
• insulin resistance
• metabolic syndrome
• type 2 diabetes mellitus

Small intestinal bacterial overgrowth (SIBO) may coexist with Helicobacter pylori infection, which can be the cause of chronic gastrointestinal complaints.

Evaluation of the therapeutic efficacy of amoxicillin and rifaximin in the treatment of these diseases.

The lactulose hydrogen breath test (LHBT) and the urea breath test (¹³C-UBT) were performed in 116 patients. In 62 patients the coexistence of small intestinal bacterial overgrowth and H. pylori infection was observed. Then, in group I (n = 30) pantoprazole (2 × 40 mg), amoxicillin (2 × 1000 mg) and metronidazole (2 × 500 mg) and in group II (n = 32) pantoprazole and amoxicillin at the above doses and rifaximin (3 × 400 mg) were administered for 10 days. After 6 weeks, both breath tests were repeated and the degree of remission of symptoms was measured using a 10-point visual analog scale (VAS).

After the treatment the LHBT index decreased in group I from 61.2 ±19.4 ppm to 22.0 ±8.2 ppm (p < 0.001) and in group II from 59.6 ±15.5 ppm to 15.2 ±8.6 ppm (p < 0.001). Eradication of H. pylori (¹³C-UBT below 4.0‰) was achieved in 63.3% of patients in group I and 59.4% in group II (p > 0.05). The decrease of pain below 3.0 points in the VAS was obtained in 64.8% of patients in group I and in 56.2% in group II.

Combination of amoxicillin and rifaximin may be effective in the treatment of patients with small intestinal bacterial overgrowth syndrome and concomitant H. pylori infection.

• Helicobacter pylori
• amoxicillin
• rifaximin
• small intestinal bacterial overgrowth
• therapy

• Dyspepsia
• Helicobacter pylori
• Metabolic syndrome
• Treatment

• Adolescent
• Adult
• Aged
• Blood Glucose/analysis
• Disease Eradication
• Dyspepsia/blood
• Dyspepsia/prevention & control
• Female
• Glycated Hemoglobin/analysis
• Helicobacter pylori/drug effects
• Humans
• Lipids/blood
• Male
• Metabolic Syndrome/blood
• Metabolic Syndrome/prevention & control
• Middle Aged
• Young Adult

To explore the association between Helicobacter pylori (H. pylori) infection and obesity/weight gain in a Chinese population.

Our primary outcome was the change in body mass index (BMI). The generalized linear models were used to explore the association between H. pylori infection and the change of BMI, and the logistic regression models were used to explore the association between H. pylori infection and obesity.

A total of 3039 subjects were recruited and analyzed, of which 12.8% were obese. The prevalence of H. pylori infection was 53.9% (1639/3039) overall and 54.6% (212/388) in the obese subjects. The change of BMI in the H. pylori (+) group was not significantly higher than that in the H. pylori (-) group after adjustment for potential confounding factors [RR = 0.988, 95%CI: 0.924-1.057, P = 0.729]. The prevalence of obesity decreased 1.1% in the H. pylori (+) group and 0.5% in the H. pylori (-) group. The RR of H. pylori infection for obesity was 0.831 (95%CI: 0.577-1.197, P = 0.321) after the adjustment.

H. pylori infection was not associated with overweight/obesity observed from the retrospective study in this Chinese population.

• Obesity
• Helicobacter pylori
• Retrospective study
• China

• Adult
• Body Mass Index
• Female
• Helicobacter Infections/complications
• Helicobacter pylori/isolation & purification
• Humans
• Male
• Middle Aged
• Obesity/microbiology
• Retrospective Studies

To investigate the relationship between Helicobacter pylori (H. pylori) infection and type 2 diabetes complications, to provide guidance for prevention and treatment of diabetes complications.

One hundred and thirty-one patients with type 2 diabetes who underwent gastric mucosa biopsy staining to determine H. pylori infection were divided into an H. pylori positive group (n = 62) and an H. pylori negative group (n = 69). Diabetic vascular lesions were diagnosed by color Doppler ultrasound, diabetic nephropathy was diagnosed by the urine trace albumin(ALB) and 24 h urinary protein test, diabetic retinopathy diagnosed by ophthalmic fundus examination, and diabetic peripheral neuropathy by electromyography or clinical symptoms. The relationship between H. pylori infection and the above-mentioned diabetes complications was then analyzed.

In the H. pylori positive group, the incidence rate of diabetic vascular lesions was 62.9%, the incidence rate of diabetic nephropathy was 27.4%, and the incidence rate of diabetic peripheral neuropathy was 56.4%, all of which were significantly higher than those of the H. pylori negative group (P < 0.05). ALB and 24 h urinary protein in the H. pylori positive group were significantly higher than those of the H. pylori negative group (P < 0.05).

There is a close relationship between H. pylori infection and diabetic vascular lesions, diabetic nephropathy, and diabetic peripheral neuropathy. Anti-H. pylori treatment can help reduce the occurrence and development of diabetic complications.

• Diabetes mellitus
• Complication
• Helicobacter pylori

Helicobacter pylori (H. pylori) is an ancient microorganism that has co-evolved with humans for over 60000 years. This bacterium typically colonizes the human stomach and it is currently recognized as the most common infectious pathogen of the gastroduodenal tract. Although its chronic infection is associated with gastritis, peptic ulcer, dysplasia, neoplasia, MALT lymphoma and gastric adenocarcinoma, it has been suggested the possible association of H. pylori infection with several extragastric effects including hepatobiliary and pancreatic diseases. Since a microorganism resembling H. pylori was detected in samples from patients with hepatobiliary disorders, several reports have been discussed the possible role of bacteria in hepatic diseases as hepatocellular carcinoma, cirrhosis and hepatic encephalopathy, nonalcoholic fatty liver disease and fibrosis. Additionally, studies have reported the possible association between H. pylori infection and pancreatic diseases, especially because it has been suggested that this infection could change the pancreatic physiology. Some of them have related a possible association between the microorganism and pancreatic cancer. H. pylori infection has also been suggested to play a role in the acute and chronic pancreatitis pathogenesis, autoimmune pancreatitis, diabetes mellitus and metabolic syndrome. Considering that association of H. pylori to liver and pancreas diseases needs further clarification, our work offers a review about the results of some investigations related to the potential pathogenicity of H. pylori in these extragastric diseases.

• Hepatocellular carcinoma
• Cirrhosis
• Hepatic encephalopathy
• Helicobacter pylori
• Nonalcoholic fatty liver disease
• Fibrosis
• Pancreatitis
• Pancreatic cancer
• Diabetes mellitus
• Metabolic syndrome

This study aimed to analyze the influence of H. pylori infection on insulin resistance and metabolic syndrome (MS) by multivariate analysis of a community-based cohort study. From January 2013 to February 2014,811 subjects were enrolled in a community-based cohort study from the northeastern region of Taiwan. All subjects received a demographic survey and blood tests, including an H. pylori antibody test, liver biochemistry tests, lipid profiles, sugar/insulin levels for Homeostatic model assessment (HOMA-IR index), and measurements of adipokines and inflammatory cytokines. A total of 264 men and 547 women were included in this study. The mean age was 59.2 ± 12.7 years. Subjects seropositive for H. pylori antibodies exhibited higher rates of hypertension, an increased incidence of a HOMA-IR index > 2.5 and a higher level of tumor necrosis factor-α than those without H. pylori antibodies. We found a significant difference in the presence of H. pylori antibodies between subjects with MS and those without MS (76.7% vs. 53.7%, p = 0.007) among subjects < 50 y/o. A HOMA-IR index >2.5, H. pylori antibody presence and leptin were predictors for MS in subjects < 50 y/o. The estimated odds ratio of MS for a subject with H. pylori antibodies was 3.717 (95% CI = 1.086–12.719) times that of a subject without H. pylori antibodies. In addition, no difference in H. pylori antibody status was detected for MS prediction in subjects that were ≧ 50 y/o (p = 0.861). In conclusion, subjects with H. pylori antibodies had a higher incidence of a HOMA-IR >2.5 than those without H pylori antibodies. For subjects aged < 50 y/o, the H. pylori antibody was a predictor for MS.

• Age Factors
• Aged
• Antibodies, Bacterial/blood
• Case-Control Studies
• Female
• Helicobacter Infections/blood
• Helicobacter Infections/epidemiology
• Helicobacter Infections/physiopathology
• Helicobacter pylori
• Humans
• Hypertension/blood
• Hypertension/epidemiology
• Hypertension/microbiology
• Hypertension/physiopathology
• Insulin Resistance
• Leptin/blood
• Male
• Metabolic Syndrome/blood
• Metabolic Syndrome/epidemiology
• Metabolic Syndrome/microbiology
• Metabolic Syndrome/physiopathology
• Middle Aged
• Taiwan

• Helicobacter pylori
• cytotoxin-associated gene A
• thyroid function test

• Adult
• Antigens, Bacterial/blood
• Bacterial Proteins/blood
• Dyspepsia/blood
• Female
• Hashimoto Disease/blood
• Hashimoto Disease/diagnostic imaging
• Helicobacter Infections/blood
• Helicobacter pylori/pathogenicity
• Humans
• Male
• Middle Aged
• Risk Factors
• Thyroid Function Tests
• Thyroid Gland/diagnostic imaging
• Ultrasonography

• Body mass index and hypertension
• Helicobacter pylori
• diabetes mellitus
• glucose level
• lipid profile
• triglyceride and cholesterol

• Extraintestinal disorders
• Gastroduodenal diseases
• Helicobacter pylori
• Host factors
• Virulence factor

• Cardiovascular Diseases/complications
• Colorectal Neoplasms/complications
• Comorbidity
• Genomic Islands
• Helicobacter Infections/microbiology
• Helicobacter Infections/physiopathology
• Helicobacter pylori/genetics
• Hematologic Diseases/complications
• Humans
• Immune System
• Insulin Resistance
• Pancreatic Neoplasms/complications
• Peptic Ulcer/complications
• Risk Factors
• Skin Diseases/complications
• Stomach Neoplasms/complications
• Treatment Outcome
• Virulence Factors

• CagA
• Epigenetic changes
• Gastric cancer
• Helicobacter pylori
• VacA

• Animals
• Cell Transformation, Neoplastic/immunology
• Cell Transformation, Neoplastic/metabolism
• Disease Progression
• Gastric Mucosa/immunology
• Gastric Mucosa/metabolism
• Gastric Mucosa/microbiology
• Gastritis/epidemiology
• Gastritis/immunology
• Gastritis/metabolism
• Gastritis/microbiology
• Helicobacter Infections/epidemiology
• Helicobacter Infections/metabolism
• Helicobacter Infections/microbiology
• Helicobacter pylori/immunology
• Helicobacter pylori/metabolism
• Helicobacter pylori/pathogenicity
• Humans
• Immunity, Mucosal
• Inflammation Mediators/metabolism
• Risk Factors
• Signal Transduction
• Stomach Neoplasms/epidemiology
• Stomach Neoplasms/immunology
• Stomach Neoplasms/metabolism
• Stomach Neoplasms/microbiology
• Virulence Factors/metabolism

• esophageal motility disorders
• gastroesophageal reflux
• obesity

L'infection à Hélicobacter pylori concerne la moitié de la population mondiale, principalement dans les pays en voie de développement où l'infection atteint 80% de la population. Le but de notre étude était de déterminer la prévalence de l'infection à Hélicobacter pylori et de mettre en évidence les déterminants de l'infection ainsi que les maladies associées au Cameroun.

L’étude concernait 171 sujets symptomatiques référés pour une fibroscopie œsogastroduodénale au Centre Hospitalier et Universitaire de Yaoundé et au Centre Médical la Cathédrale. L'infection à H.pylori était objectivée par un test rapide à l'uréase kit commercial Pronto Dry^® (Medical Instruments Corporation, Solothurn, Switzerland).

La prévalence globale de l'infection à Hélicobacter pylori était de 72,5% (124/171) (Intervalle de Confiance (IC) à 95% 65,2-79,1%) et dans chaque groupe d’âge (moins de 40ans, 40-50ans, plus de 50ans) de 83,1%(64/77), 67,4%(29/43) et 60,8%(31/51) respectivement. En analyse univariée, le risque de l'infection était significativement élevé dans le groupe de moins de 40ans comparé au groupe de 40-50ans (Risque Relatif (RR) 0,42 IC 95% 0,16-1,1, p = 0,04 pour le groupe 40-50ans) et comparé au groupe de plus de 50ans (RR 0,73; 0,57-0,93, p = 0,004 pour le groupe de plus de 50ans). La prévalence de l'infection à H.pylori était de 63,0% (17/27) pour l'ulcère duodénal, 50%(4/8) pour l'ulcère gastrique et 100%(2/2) pour le cancer gastrique.

A prévalence de l'infection à H.pylori au Cameroun est très élevée et significativement liée à l’âge de moins de 40 ans.

• African enigma
• Cameroon
• Epidemiology
• Helicobacter pylori
• developing countries